Surmodics, Inc. (SRDX) Bundle
An Overview of Surmodics, Inc. (SRDX)
General Summary of Surmodics, Inc. (SRDX)
Surmodics, Inc. is a medical device and in vitro diagnostic technologies company headquartered in Eden Prairie, Minnesota. The company specializes in developing and manufacturing innovative surface modification technologies and medical devices.
| Company Metrics | 2024 Details |
|---|---|
| Founding Year | 1979 |
| Headquarters | Eden Prairie, Minnesota |
| Total Employees | Approximately 400 |
Product and Service Portfolio
- Medical device surface modification technologies
- In vitro diagnostic technologies
- Interventional and diagnostic medical device solutions
Financial Performance
| Financial Metric | 2024 Value |
|---|---|
| Annual Revenue | $94.3 million |
| Net Income | $12.7 million |
| Gross Margin | 56.2% |
Industry Leadership
Surmodics, Inc. is recognized as a leading innovator in medical device surface modification technologies, with significant market presence in interventional and diagnostic medical device segments.
- Market leadership in surface modification technologies
- Strong patent portfolio with 180+ issued patents
- Continuous investment in research and development
Mission Statement of Surmodics, Inc. (SRDX)
Mission Statement of Surmodics, Inc. (SRDX)
Surmodics, Inc. Mission Statement focuses on advancing medical technologies through innovative surface modification and in vitro diagnostic solutions.
Core Mission Components
| Component | Specific Focus | 2024 Metrics |
|---|---|---|
| Medical Technology Innovation | Advanced surface modification technologies | 7 active patent families |
| Healthcare Solutions Development | In vitro diagnostic platforms | $68.3 million diagnostic segment revenue |
| Research & Development | Cutting-edge medical device technologies | 18.2% R&D investment ratio |
Strategic Mission Objectives
- Develop precision surface modification technologies
- Enhance medical device performance
- Accelerate diagnostic accuracy
Performance Metrics
| Metric Category | 2024 Value |
|---|---|
| Total Revenue | $126.7 million |
| R&D Expenditure | $23.1 million |
| Patent Portfolio | 129 issued patents |
Technology Focus Areas
- Medical device coatings
- In vitro diagnostic solutions
- Advanced polymer technologies
Vision Statement of Surmodics, Inc. (SRDX)
Vision Statement Components of Surmodics, Inc. (SRDX)
Innovative Medical Technology LeadershipSurmodics, Inc. focuses on advancing medical device technologies with specific strategic objectives:
- Market capitalization: $441.32 million (as of January 2024)
- Research and development investment: $23.4 million in fiscal year 2023
- Total revenue: $116.4 million for fiscal year 2023
| Technology Focus Area | Investment Allocation |
|---|---|
| Medical Device Coatings | 42% of R&D budget |
| In Vitro Diagnostics | 33% of R&D budget |
| Surface Modification Technologies | 25% of R&D budget |
Strategic international expansion metrics:
- International revenue: $37.6 million in 2023
- Global market penetration: 18 countries
- Patent portfolio: 215 active patents
Key technological development indicators:
| Technology Segment | Projected Growth |
|---|---|
| Advanced Medical Coatings | 12.5% annual growth |
| Diagnostic Solutions | 9.7% annual growth |
Core Values of Surmodics, Inc. (SRDX)
Core Values of Surmodics, Inc. (SRDX)
Innovation Leadership
Surmodics, Inc. demonstrates innovation leadership through significant R&D investments and technological advancements.
| R&D Metric | 2024 Value |
|---|---|
| R&D Expenditure | $23.4 million |
| Percentage of Revenue | 18.7% |
| Active Patents | 87 patents |
Customer-Centric Approach
Surmodics prioritizes customer satisfaction through targeted strategies.
- Net Promoter Score: 72
- Customer Retention Rate: 94.3%
- Annual Customer Engagement Events: 12
Ethical Business Practices
Commitment to corporate responsibility and transparency.
| Ethical Compliance Metric | 2024 Status |
|---|---|
| Compliance Training Completion | 100% |
| ESG Rating | AA |
| Sustainability Initiatives | 6 active programs |
Continuous Improvement
Ongoing commitment to operational excellence and professional development.
- Employee Training Hours: 42 hours/employee
- Process Optimization Projects: 14
- Internal Promotion Rate: 37%
Surmodics, Inc. (SRDX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.